drugset / Trial / NCT04546126

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

NCT04546126

Phase 0 Recruiting 24 enrolled Benjamin Viglianti
Non-randomizedParallel-groupOpen-labelHealth-services research

Summary

This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.

Timeline

Start
2021-11-01
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cosyntropin Unknown 250 ug Intravenous
Subject Dexamethasone Small molecule 1 mg
Subject FNP-59 Diagnostic / imaging agent

Indications